Following two U.S. Supreme Court decisions that shut the door on state-law failure-to-warn and design-defect claims over generic drugs, the Food and Drug Administration is taking steps that could ultimately open a window for plaintiffs. The agency has stated its ...

Tagged with: Aug. 31 2031 issue

Read More »